Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01732107 · ClinicalTrials.gov registry record · Phase 2
Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
A Phase 2 study, sponsored by Noah Hahn, M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01732107: Clinical Trial Phase 2 study, sponsored by Noah Hahn, M.D..
NCT01732107 is a Phase 2 study that was terminated before completion, run by Noah Hahn, M.D.. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01732107, a Phase 2 study, was terminated before completion, sponsored by Noah Hahn, M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This trial will assess the 6-month complete response rate and toxicity profile of oral dovitinib therapy in BCG-refractory urothelial carcinoma patients with tumors with FGFR3 mutations or over-expression who are ineligible for or refusing cystectomy.
Primary Outcome
The 6-month complete response rate is defined as the proportion of patients treated with dovitinib with no evidence of any remaining urothelial carcinoma tumors of any T-stage (including Tis) present within the bladder as assessed by standard of care cystoscopic examination with transurethral resection of bladder tumor (TURBT) and urine cytology performed at 6 months after initiation of study therapy.
Interventions
- DRUG Dovitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-03 |
| Est. Completion | 2017-03-06 |
| Phase | Phase 2 |
Why NCT01732107 stopped before completion
NCT01732107 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Dovitinib is the first listed.
NCT01732107 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01732107 about?
NCT01732107 is a clinical study titled "Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression". This trial will assess the 6-month complete response rate and toxicity profile of oral dovitinib therapy in BCG-refractory urothelial carcinoma patients with tumors with FGFR3 mutations or over-expression who are ineligible for or refusing cystectomy.
What is the current status of trial NCT01732107?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2013-03. Estimated completion is 2017-03-06.
What interventions are being tested in trial NCT01732107?
The interventions under investigation include: Dovitinib (DRUG).
Who is sponsoring clinical trial NCT01732107?
This trial is sponsored by Noah Hahn, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01732107's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia